Fusarium keratitis in Brazil: genotyping, in vitro susceptibilities, and clinical outcomes

Background: The purpose of this paper is to describe clinical characteristics and determine correlations between clinical outcomes and antifungal susceptibility among molecularly char-acterized ocular Fusarium isolates in Brazil. Methods: Forty-one Fusarium isolates obtained from 41 eyes of 41 patients were retrieved from the ophthalmic microbiology laboratory at São Paulo Federal University and grown in pure culture. These isolates were genotyped and antifungal susceptibilities determined for each isolate using a broth microdilution method. The corresponding medical records were reviewed to determine clinical outcomes. Results: The 41 isolates were genotypically classified as Fusarium solani species complex (36 isolates, 88%), Fusarium oxysporum species complex (two isolates, 5%), Fusarium dimerum species complex (one isolate, 2%) and two isolates that did not group into any of the species complexes. Final best corrected visual acuity varied from 20/20 to light perception and was on average 20/800 (logarithm of the minimum angle of resolution (LogMAR) 1.6). A history of trauma was the most common risk factor, being present in 21 patients (51%). Therapeutic penetrating keratoplasty was necessary in 22 patients (54%). Amphotericin B had the lowest minimum inhibitory concentration for 90% of isolates (MIC 90 ) value (2 µ g/mL) and voriconazole had the highest (16 µ g/mL). There was an association between a higher natamycin MIC and need for therapeutic penetrating keratoplasty (Mann–Whitney test, P , 0.005). Conclusion: Trauma was the main risk factor, and therapeutic penetrating keratoplasty was necessary in 54% of patients. Amphotericin B had the lowest MIC 90 (2 µ g/mL) of the three antifungal agents tested. There was an association between higher natamycin MIC levels and corneal perforation, emphasizing the need for antifungal susceptibility testing and tailoring of antifungal strategies.

[1]  W. Shi,et al.  Fusarium Keratitis: Genotyping, In Vitro Susceptibility and Clinical Outcomes , 2013, Cornea.

[2]  M. Ghannoum,et al.  Characterization of fusarium keratitis outbreak isolates: contribution of biofilms to antimicrobial resistance and pathogenesis. , 2012, Investigative ophthalmology & visual science.

[3]  M. Srinivasan,et al.  Organism, Minimum Inhibitory Concentration, and Outcome in a Fungal Corneal Ulcer Clinical Trial , 2012, Cornea.

[4]  D. Glidden,et al.  Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Savitri Sharma,et al.  Diagnosis and treatment outcome of mycotic keratitis at a tertiary eye care center in eastern india , 2011, BMC ophthalmology.

[6]  Savitri Sharma,et al.  Natamycin in the treatment of keratomycosis: Correlation of treatment outcome and in vitro susceptibility of fungal isolates , 2011, Indian journal of ophthalmology.

[7]  Emily W. Gower,et al.  Clinical and microbiological characteristics of fungal keratitis in the United States, 2001-2007: a multicenter study. , 2011, Ophthalmology.

[8]  M. Yu,et al.  Microbial keratitis at a referral center in Brazil , 2011, International Ophthalmology.

[9]  T. Sorrell,et al.  Accurate and Practical Identification of 20 Fusarium Species by Seven-Locus Sequence Analysis and Reverse Line Blot Hybridization, and an In Vitro Antifungal Susceptibility Study , 2011, Journal of Clinical Microbiology.

[10]  E. S. Arcieri,et al.  Epidemiology and Etiologic Diagnosis of Infectious Keratitis in Uberlandia, Brazil , 2010, European journal of ophthalmology.

[11]  M. Fini,et al.  Utility of molecular sequence analysis of the ITS rRNA region for identification of Fusarium spp. from ocular sources. , 2009, Investigative ophthalmology & visual science.

[12]  M. Srinivasan,et al.  Susceptibility testing and clinical outcome in fungal keratitis , 2009, British Journal of Ophthalmology.

[13]  E. Rocha,et al.  Epidemiologic Aspects and Clinical Outcome of Fungal Keratitis in Southeastern Brazil , 2009, European journal of ophthalmology.

[14]  P. Lalitha,et al.  In Vitro Natamycin Susceptibility of Ocular Isolates of Fusarium and Aspergillus Species: Comparison of Commercially Formulated Natamycin Eye Drops to Pharmaceutical-Grade Powder , 2008, Journal of Clinical Microbiology.

[15]  D. Posada.  jModelTest: phylogenetic model averaging. , 2008, Molecular biology and evolution.

[16]  C. Gianni,et al.  Species Distribution and In Vitro Antifungal Susceptibility Patterns of 75 Clinical Isolates of Fusarium spp. from Northern Italy , 2008, Antimicrobial Agents and Chemotherapy.

[17]  M. Srinivasan,et al.  Does in vitro susceptibility predict clinical outcome in bacterial keratitis? , 2008, American journal of ophthalmology.

[18]  M. Nei,et al.  MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. , 2007, Molecular biology and evolution.

[19]  S. Tuli,et al.  Fungal Keratitis: Emerging Trends and Treatment Outcomes , 2006, Eye & contact lens.

[20]  Weiyun Shi,et al.  Spectrum of fungal keratitis in north China. , 2006, Ophthalmology.

[21]  Wuqaas M. Munir,et al.  Insurgence of Fusarium keratitis associated with contact lens wear. , 2006, Archives of ophthalmology.

[22]  S. Mccormick,et al.  Fungal Keratitis at the New York Eye and Ear Infirmary , 2006, Cornea.

[23]  J. Guarro,et al.  Genotyping of 44 Isolates of Fusarium solani, the Main Agent of Fungal Keratitis in Brazil , 2004, Journal of Clinical Microbiology.

[24]  J. Giaconi,et al.  In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. , 2004, American journal of ophthalmology.

[25]  John P. Huelsenbeck,et al.  MRBAYES: Bayesian inference of phylogenetic trees , 2001, Bioinform..

[26]  E. Cohen,et al.  Spectrum of Fungal Keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania , 2000, Cornea.

[27]  A. Espinel-Ingroff.  In Vitro Activity of the New Triazole Voriconazole (UK-109,496) against Opportunistic Filamentous and Dimorphic Fungi and Common and Emerging Yeast Pathogens , 1998, Journal of Clinical Microbiology.

[28]  T. Wong,et al.  Risk factors and clinical outcomes between fungal and bacterial keratitis: a comparative study. , 1997, The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc.

[29]  K Bandeen-Roche,et al.  Functional status and quality of life measurement among ophthalmic patients. , 1994, Archives of ophthalmology.

[30]  E. Anaissie,et al.  Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method , 1989, Antimicrobial Agents and Chemotherapy.

[31]  P. McDonnell,et al.  Bacterial susceptibility to topical antimicrobials and clinical outcome in bacterial keratitis. , 2010, Investigative ophthalmology & visual science.

[32]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of filamentous fungi : Approved standard , 2008 .

[33]  A. Chowdhary,et al.  Spectrum of fungal keratitis in North India. , 2005, Cornea.

[34]  D. Freitas,et al.  [Laboratory study of the mycotic infectious eye diseases and factors associated with keratitis]. , 2005, Arquivos brasileiros de oftalmologia.

[35]  Kathleen A. Boyle,et al.  In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature , 2004, Mycopathologia.

[36]  J. Clanton,et al.  Corneal penetration of topical amphotericin B and natamycin. , 1986, Current eye research.